Insulinoma

Wilder RM, Allan FH, Power MH, Robertson HE. Carcinoma of the islets of the pancreas: Hyperinsulinism and hypoglycemia. JAMA 1927; 89: 348-55.

Service FJ, McMahon MM, O'Brien PC, Ballard DJ. Functioning insulinoma-incidence, recurrence, and longterm survival of patients: a 60-year study. Mayo Clin Proc 1991;66:711-19.

Dizon AM, Kowalyk S, Hoogwerf BJ. Neuroglycopenic and other symptoms in patients with insulinomas. Am I Med 1999; 106: 307-10.

Whipple AO. The surgical therapy of hyperinsulinism. J Int Chir 1938; 3:237-76.

Harrington MG, McGeorge AP, Ballantyne JP, Beastall G.A prospective survey for insulinomas in a neurology department. Lancet 1983; 1: 1094-5.

Graves TD, Gandhi S, Smith SJ, Sisodiya SM, Conway GS. Misdiagnosis of seizures: insulinoma presenting as adult-onset seizure disonder. J Neurol Neurosurg Psychiatry 2004; 75: 1091-2.

Service FJ, Dale AJ, Elveback LR, Jiang NS. Insulinoma: clinical and diagnostic features of 60 consecutive cases. Mayo Clin Proc 1976; 51:417-29.

Service FJ. Hypoglycemic disorders.N Engl I Med 1995; 332:1144-52.

Service FJ, O'Brien PC, McMahon MM, Kao PC.C- peptide during the prolonged fast in insulinoma. Clin Endocrinol Metab 1993; 76: 655-9.

Modlin IM, Tang LH. Approaches to the diagnosis of gut neuroendocrine tumors: the last word (today). Gastroenterology 1997; 112: 583-90.

Doherty GM, Doppman JL, Shawker TH, Miller DL, Eastman RC, Gorden P,etal. Results of a prospective strategy to diagnose, localize, and resect insulinomas. Surgery 1991; 110:989-96.

Wiesli P, Brandle M, Schmid C,Krahenbubl L, Furrer J, Keller U, et al. Selective arterial calcium stimulation and hepatic venous sampling in the evaluation of hyperinsulinemic hypoglycemia: potential and limitations. I Vasc Interv Radiol 2004; 15: 1251-6.

Starke AA, Frilling A, Becker H, Roher HD, Berger M. Are CAT-scans necessary for preoperative localization of insulinomas?. Eur I Med 1992; 1:411-3.

Marks V, Rose FC, Samols E. Hyperinsulinism due to metastasizing insulinoma: treatment with diazoxide. Proc R Soc Med 1965; 58: 577-8.

Gill GV, Rauf O, MacFarlane IA. Diazoxide treatment for insulinoma: a national UK survey. Postgrad Med J 1997; 73: 640-1.

Goode PN, Farndon JR, Anderson J, Johnston ID, Morte JA. Diazoxide in the management of patients with insulinoma. World J Surg 1986; 10: 586-92.

Shaer AJ. Management of hyperinsulinemia with diazoxide in an elderly hemodialysis patient. Nephron 2001; 89:337-9.

Cohen MS, Bower RH, Fidler SM, Johnsonbaugh RE, Sode J. Inhibition of insulin release by diphenylhydantoin and diazoxide in a patient with benign insulinoma. Lancet 1973; 1:40-1.

Imanaka S, Matsuda S, Ito K, Matsuoka T, Okada Y. Medical treatment for inoperable insulinoma: clinical usefulness of diphenylhydantoin and diltiazem. Jpn J Clin Oncol 1986; 16: 65-71.

von Eyben FE, Grodum E, Gjessing HJ, Hagen C, Nielsen H. Metabolic remission with octreotide in patients with insulinoma. J Intern Med 1994; 235: 245-8.

Longnecker SM. Remission of symptoms of chemotherapy- refractory metastatic insulinoma using octreotide. Drug Intell Clin Pharm 1988; 22: 136-8.

Tanaka Y, Funahashi H, Imai T, Naruse T, Suzumura K, Oda Y. The effectiveness of administering a minimal

dose of octreotide long-term prior to surgery for insulinoma: report of a case. Surg Today 2000; 30: 541-3.

Craig CE, Gallen IW. Possible functional regression of insulinoma with prolonged octreotide. Postgrad Med J

; 78:623-4.

Stehouwer CD, Lems WF, Fischer HR, Hackeng WH, Naafs MA. Aggravation of hypoglycemia in insulinoma

patients by the long-acting somatostatin analogue octreotide (Sandostatin). Acta Endocrinol (Copenh)1989;12121:34-40.